Precision Biosciences Inc (DTIL) — Titan Protect Analysis

DTIL

Precision Biosciences Inc

Healthcare · ·

$6.50

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$163M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-3.30

Based on estimated future earnings — lower means cheaper

Rev Growth

+37,272.4%

Year-over-year revenue change

Profit Margin

-96.7%

How much profit the company keeps from each dollar of revenue

ROE

-70.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$24.50

+277% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 4 analysts covering this stock

About Precision Biosciences Inc

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with t

https://precisionbiosciences.com

Country: United States Employees: 66 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

DISTRIBUTION

Smart money appears to be selling into strength — caution

Sharpe Ratio

-0.129

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0290

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.413

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-30.0%

Historical annualised return based on price data

Max Drawdown

-72.6%

Largest peak-to-trough decline — the worst it has been

HMM State

SIDEWAYS

Price consolidating — no clear directional bias

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

1.31

Moves slightly more than the broader market

52W High

$8.82

26% below the year high

52W Low

$3.53

84% above the year low

Avg Volume

306,533

Average daily shares traded — higher means easier to buy and sell

Short Ratio

7.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.17

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

37.41

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

100.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-83.7%

Profit from core operations before interest and tax

Free Cash Flow

$-21,668,250

Negative — the business is spending more than it generates

Revenue (TTM)

$45M

Total revenue over the last 12 months

Net Income

$-44,485,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$60.00

Target Median

$24.50

Target Low

$19.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go